NCT06452706招募中2 期
The Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection in Human Epidermal Growth Factor Receptor 2 (HER2) Negative Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.16 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2024年11月14日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 16
- 主要终点
- Objective response rate
研究概览
简要总结
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participants voluntarily participate in the study and sign an informed consent form.
- •Age: 18-75 years old; Eastern Cooperative Oncology Group (ECOG) score: ≤1 point; Expected survival period exceeds 3 months.
- •Breast cancer patients diagnosed as HER2 negative by pathology, with evidence of local recurrence or distant metastasis are not suitable for surgery or radiation therapy aimed at healing.
- •Sufficient tumor tissue samples must be available for HER2 evaluation by pathologists at the main research center.
- •The participants's previous treatment needs to meet the following criteria: failure after receiving at least first-line systemic chemotherapy during the recurrence /metastasis stage (for hormone receptor positive participants, failure after receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy during the recurrence/metastasis stage.
- •There exists disease progression or intolerance during or after the most recent treatment before enrollment.
- •According to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 standard, there should be at least one measurable lesion.
- •The main organ functions well and meets certain standards.
- •Female participants of childbearing age should agree to use contraceptive measures during the study period and within 6 months after the end of the study; within 7 days prior to enrollment, the serum pregnancy test was negative and must be a non lactating subject; male participants should agree to adopt avoidance measures during the study period and within 6 months after the end of the study period.
排除标准
- •Concomitant diseases and medical history:
- •Have experienced or currently suffer from other malignant tumors within 5 years prior to the first medication use;
- •Uncontrollable toxic reactions above CTCAE level 1 caused by any previous treatment;
- •Received significant surgical treatment or significant traumatic injury within 28 days prior to the first medication use;
- •Long term unhealed wounds or fractures;
- •Participants who have a history of interstitial lung disease/pneumonia (non infectious) requiring steroid intervention treatment in the past, or currently have interstitial lung disease/pneumonia, or whose screening imaging suggests suspected interstitial lung disease/pneumonia and cannot be ruled out;
- •An arterial/venous thrombotic event occurred within 6 months prior to the first medication use;
- •Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
- •Subjects with any severe and/or uncontrolled diseases. Rheumatoid arthritis with joint function activity graded as Grade IV or requiring wheelchair or bed rest.
- •Tumor related symptoms and treatment:
- •Participants who have received other anti-tumor drug treatments such as chemotherapy, curative radiotherapy, or immunotherapy within 4 weeks before the first medication, or who are still within the 5 half-lives of the drug (whichever is the shortest); Participants who have previously received local radiotherapy;
- •Received endocrine therapy or traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug directions within 2 weeks before the first drug use;
- •Imaging shows that the tumor has invaded important blood vessels, or the researcher determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
- •Uncontrollable pleural effusion, ascites, and moderate or higher amounts of pericardial effusion that require repeated drainage;
- •Known presence of cancerous meningitis or clinically active central nervous system metastasis;
- •Severe bone damage caused by tumor bone metastasis. Suffering from lung diseases that have been determined by the researcher to be unsuitable for participation in this study.
- •Individuals who are known to be allergic to the investigational drug or its excipients, or allergic to humanized monoclonal antibody products.
- •Individuals who have participated in and used other anti-tumor clinical trial drugs within 4 weeks prior to the first medication use.
- •According to the judgment of the researchers, there are situations that seriously endanger the safety of the subjects or affect their completion of the study.
研究组 & 干预措施
TQB2102 for injection
Experimental
7.5mg/kg TQB2102, intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
干预措施: TQB2102 for injection (Drug)
结局指标
主要结局
Objective response rate
时间窗: Up to 24 months after study start.
The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the RECIST 1.1.
次要结局
- Duration of disease remission(Up to 24 months after study start)
- Disease control rate(Up to 24 months after study start)
- Progression-free survival(Up to 36 months after study start)
- Overall survival(Up to 48 months after study start)
- Clinical benefit rate(Up to 24 months after study start)
- Incidence of adverse events(Up to 36 months after study start)
- Anti-drug antibody (ADA)(1 hour Before infusion on Cycle 1 Day1, Cycle 2 Day1, Cycle 4 Day1, Cycle 7 Day1, Cycle 12 Day1, and 30 days after the end of the last infusion. Each cycle is 21 days)
- HER2(Up to 24 months after study start)
- circulating tumor DNA (ctDNA)(Up to 24 months after study start)
研究者
研究点 (16)
Loading locations...
相似试验
招募中
1 期
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerBiliary Tract CancerNCT06431490Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102
终止
2 期
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)Relapsed/Refractory LeukemiaNCT00724360Nantes University Hospital15
已完成
2 期
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT05563480Chia Tai Tianqing Pharmaceutical Group Co., Ltd.47
已完成
2 期
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab TherapyBreast NeoplasmsNCT00431067Boehringer Ingelheim41
招募中
2 期
Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2Salivary Gland TumorsNCT05601401Peking Union Medical College Hospital10